| Authors: |
Salaun B; GSK, Rue de l'Institut, Rixensart, Belgium., De Smedt J; GSK, Rue de l'Institut, Rixensart, Belgium., Vernhes C; Sanofi, Lyon, France., Moureau A; Sanofi, Lyon, France., Öner D; Biomarkers Infectious Diseases, Janssen Pharmaceutica NV, Beerse, Belgium., Bastian AR; Janssen Vaccines & Prevention B.V., Leiden, Netherlands., Janssens M; GSK, Rue de l'Institut, Rixensart, Belgium., Balla-Jhagjhoorsingh S; Janssen Vaccines & Prevention B.V., Leiden, Netherlands., Aerssens J; Biomarkers Infectious Diseases, Janssen Pharmaceutica NV, Beerse, Belgium., Lambert C; GSK, Rue de l'Institut, Rixensart, Belgium., Coenen S; Centre for General Practice, Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium.; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium., Butler CC; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom., Drysdale SB; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the National Institute for Health and care Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom., Wildenbeest JG; Department of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands., Pollard AJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the National Institute for Health and care Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom., Openshaw PJM; National Heart and Lung Institute , Imperial College London, London, United Kingdom., Bont L; Department of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands.; ReSViNET Foundation, Julius Clinical, Zeist, Netherlands. |
